Greenwich LifeSciences(GLSI)
$14.94-0.34 (-2.23%)
GLSI
Greenwich LifeSciences stock drug pipeline
$14.94
At close:-0.34 (-2.23%)
Greenwich LifeSciences (GLSI) Drug Pipeline
451 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Glsi-100 | Breast Cancer | Phase III | Recruiting | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Jan 31, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Glsi-100 | Phase III | Breast Cancer | Recruiting | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Jan 31, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Greenwich Lifesciences, Inc. (GLSI) have in its pipeline
Greenwich LifeSciences GLSI is currently developing the following drugs: Glsi-100. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

